AU2013283281B2 - Nalmefene for reduction of alcohol consumption in specific target populations - Google Patents

Nalmefene for reduction of alcohol consumption in specific target populations Download PDF

Info

Publication number
AU2013283281B2
AU2013283281B2 AU2013283281A AU2013283281A AU2013283281B2 AU 2013283281 B2 AU2013283281 B2 AU 2013283281B2 AU 2013283281 A AU2013283281 A AU 2013283281A AU 2013283281 A AU2013283281 A AU 2013283281A AU 2013283281 B2 AU2013283281 B2 AU 2013283281B2
Authority
AU
Australia
Prior art keywords
nalmefene
patient
longer
alcohol
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013283281A
Other languages
English (en)
Other versions
AU2013283281A1 (en
Inventor
Afsaneh ABBARIKI
Anna Bladstrom
Thomas Jon Jensen
Didier Meulien
Jette Buch Ostergaard
Christine PERSSON
Per Sorensen
Lars Torup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013283281(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2013283281A1 publication Critical patent/AU2013283281A1/en
Application granted granted Critical
Publication of AU2013283281B2 publication Critical patent/AU2013283281B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2013283281A 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations Ceased AU2013283281B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US61/664,804 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US61/721,539 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US61/736,740 2012-12-13
US201361788810P 2013-03-15 2013-03-15
US61/788,810 2013-03-15
PCT/EP2013/063461 WO2014001427A1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Publications (2)

Publication Number Publication Date
AU2013283281A1 AU2013283281A1 (en) 2014-12-11
AU2013283281B2 true AU2013283281B2 (en) 2017-04-20

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013283281A Ceased AU2013283281B2 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP3345604B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3138564T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2663532T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20161717T1 (enExample)
HU (4) HUE031110T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3345604T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL4223296T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3138564T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
MY158251A (en) 2009-05-25 2016-09-30 H Lundbeck As Method for the preparation of nalmefene hydrochloride
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
JP5738470B2 (ja) 2011-03-31 2015-06-24 イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア．シェ．Ｉｍｕｎｅｋｓ Ｆａｒｍａ Ｉｌａｃ Ｓａｎａｙｉ Ｖｅ Ｔｉｃａｒｅｔ Ａ．Ｓ． オピオイド拮抗体組成物、および強皮症の治療のためのその使用
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAKARI KARHUVAARA ET AL, ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., (2007), vol. 31, no. 7, pages 1179 - 1187 *
SINCLAIR JOHN DAVID, "Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism", ALCOHOL AND ALCOHOLISM, PERGAMON, OXFORD, GB, (20010101), vol. 36, no. 1, pages 2 - 10 *

Also Published As

Publication number Publication date
HRP20161717T1 (hr) 2017-02-10
WO2014001427A1 (en) 2014-01-03
EP3138564B1 (en) 2018-01-31
LT3345604T (lt) 2023-08-10
MX371373B (es) 2020-01-28
JP2018039810A (ja) 2018-03-15
KR20150023396A (ko) 2015-03-05
EP2866808A1 (en) 2015-05-06
ES2609122T3 (es) 2017-04-18
HUE031110T2 (en) 2017-06-28
EP3138564A1 (en) 2017-03-08
HRP20250329T1 (hr) 2025-05-09
HUE070621T2 (hu) 2025-06-28
SI3345604T1 (sl) 2023-08-31
JP2015521647A (ja) 2015-07-30
ES3014068T3 (en) 2025-04-16
SMT201800164T1 (it) 2018-07-17
UA114199C2 (uk) 2017-05-10
SMT201600471B (it) 2017-03-08
LT3138564T (lt) 2018-04-10
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
HRP20230762T8 (hr) 2024-01-05
EP3345604B1 (en) 2023-06-07
SG11201408704WA (en) 2015-01-29
PT2866808T (pt) 2017-01-03
EA201492152A1 (ru) 2015-11-30
EP2866808B1 (en) 2016-11-02
ME03030B (me) 2018-10-20
RS55456B1 (sr) 2017-04-28
PL2866808T3 (pl) 2017-04-28
PL3138564T3 (pl) 2018-06-29
BR112014032555A2 (pt) 2017-06-27
ES2663532T3 (es) 2018-04-13
JP6258933B2 (ja) 2018-01-10
HK1208185A1 (en) 2016-02-26
CN104411313A (zh) 2015-03-11
LT2866808T (lt) 2017-01-10
CY1118579T1 (el) 2017-07-12
DK3138564T3 (en) 2018-03-26
EP4223296B1 (en) 2025-01-29
HK1255683A1 (en) 2019-08-23
DK2866808T3 (en) 2017-01-16
CA2874703A1 (en) 2014-01-03
US20140005217A1 (en) 2014-01-02
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
PL3345604T3 (pl) 2023-08-28
PT3138564T (pt) 2018-04-03
DK3345604T3 (da) 2023-07-24
ZA201409525B (en) 2016-08-31
PT3345604T (pt) 2023-07-17
ME02587B (me) 2017-06-20
EP4223296C0 (en) 2025-01-29
FI3345604T3 (fi) 2023-07-28
ES2950492T3 (es) 2023-10-10
MX2014015488A (es) 2015-03-06
CY1126140T1 (el) 2023-11-15
EP4223296A2 (en) 2023-08-09
EP3345604A1 (en) 2018-07-11
EP4541421A2 (en) 2025-04-23
IL236035B (en) 2018-12-31
CL2014003484A1 (es) 2015-02-27
EA029908B1 (ru) 2018-05-31
PL4223296T3 (pl) 2025-04-14
US9642849B2 (en) 2017-05-09
US20140005216A1 (en) 2014-01-02
AU2013283281A1 (en) 2014-12-11
RS57046B1 (sr) 2018-05-31
CY1120097T1 (el) 2018-12-12
MY166914A (en) 2018-07-24
IL236035A0 (en) 2015-01-29
US10034874B2 (en) 2018-07-31
JP2019163275A (ja) 2019-09-26
EP4541421A3 (en) 2025-06-18
NZ702191A (en) 2017-06-30
US20180028526A1 (en) 2018-02-01
CO7160087A2 (es) 2015-01-15
HUE063313T2 (hu) 2024-01-28
JP6857684B2 (ja) 2021-04-14
CA2874703C (en) 2022-08-23
SI3138564T1 (en) 2018-04-30
EP4223296A3 (en) 2023-09-27
HRP20180363T1 (hr) 2018-04-20
RU2014151156A (ru) 2016-08-20
HRP20230762T1 (hr) 2023-10-13
HUE036272T2 (hu) 2018-06-28
SMT201600471T1 (it) 2017-03-08

Similar Documents

Publication Publication Date Title
JP6857684B2 (ja) 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
ES2337622T3 (es) Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
US9457018B2 (en) Method for combating adverse effects arising from antipsychotic treatment
RU2552290C1 (ru) Соединения опиоидных антагонистов и их применение при лечении склеродермии
HK1229720A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1229720B (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1208185B (en) Nalmefene for reduction of alcohol consumption in specific target populations
CA2909504C (en) Nalmefene for treatment of patients with mood disorder
WO2014170353A1 (en) Nalmefene for treatment of patients with sleep disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired